Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men

Supplementary Data

• Supplementary Tables 1-7 - Tables S1-S7. Table S1. Characteristics of all cases and population controls in the NCI Maryland Prostate Cancer Case-Control Study. Table S2. Pain reliever use of participants in the NCI Maryland Prostate Cancer Case-Control Study. Table S3. Adjusteda odds ratios and 95% confidence intervals for associations of regular aspirin use and prostate cancer risk in the NCI Maryland Prostate Cancer Case-Control Study. Table S4. Adjusteda odds ratios and 95% confidence intervals for associations of regular aspirin use and prostate cancer risk in men with low stageb disease compared to population controls. Table S5. Adjusteda odds ratios and 95% confidence intervals for associations of regular aspirin use and prostate cancer risk in men with high stageb disease compared to controls. Table S6. Adjusteda odds ratios and 95% Confidence intervals for associations of regular aspirin use and prostate cancer risk in men with aggressiveb disease compared to population controls. Table S7. Adjusteda odds ratios and 95% confidence intervals for associations of regular aspirin use and prostate cancer risk in men with nonaggressiveb disease compared to populations controls.
• Supplementary Figures - Supplementary Figure 1. Increased C-reactive protein (CRP) plasma level in African-American (AA) men. Differences in CRP plasma level between AA and European-American(EA) men. CRP was measured in plasma samples of cases (100 AA, 100 EA) and controls(100 AA, 100 EA).